A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy
- 207 Downloads
To compare the efficacy of 50% threshold power with 25% threshold power of 577-nm subthreshold micropulse laser (SMPL) for acute central serous chorioretinopathy (CSC). Prospective, interventional, non-randomized, comparative case series. A total of 54 patients (54 eyes) with acute CSC were enrolled. Twenty-four eyes received 25% threshold power and 30 eyes received 50% threshold power of 577-nm SMPL. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and complete absorption of subretinal fluid (SRF) were evaluated at 1 month and 3 months. The complete absorption rate of SRF in the 50% power group was significantly greater than that in the 25% power group at 1 month (70.0% vs 25.0%, p < 0.001) and at 3 months (83.3% vs 54.2%, p < 0.001). Mean BCVA improved from 0.34 ± 0.20 LogMAR to 0.02 ± 0.13 LogMAR in the 50% power group and from 0.27 ± 0.15 LogMAR to 0.14 ± 0.21 LogMAR in the 25% power group with a significant difference between the two groups after 3 months (p = 0.027). In the 50% power group, the CMT decreased from 491.6 ± 154.8 μm at baseline to 231.3 ± 92.3 μm at 1 month and 228.2 ± 88.1 μm at 3 months, and in the 25% power group, the CMT decreased from 444.9 ± 164.1 to 306.8 ± 102.6 μm at 1 month and 254.5 ± 101.7 μm at 3 months. There was statistical difference of CMT at 1 month (p = 0.009) but no significant difference at 3 months between the two groups (p = 0.232). SMPL with 50% threshold power may be more effective than 25% threshold power for acute CSC.
KeywordsSubthreshold micropulse laser Acute central serous chorioretinopathy Titration power
The authors would like to thank all staff involved in the care of patient presented in this study.
Supported by National Natural Science Foundation of China (81670866).
Compliance with ethical standards
Conflict of interest
All authors have no financial or other conflicts of interest concerning this study. VC is a consultant of Quantel Medical and an employee of Boehringer Ingelheim.
Written informed consents were obtained from the patients before treatment.
This study was approved by the Ethics Committee of Zhongshan Ophthalmic Center of Sun Yat-Sen University and was conducted in adherence with the tenets of the Declaration of Helsinki.
- 19.Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S, Shetty B, Shetty R, Medscape (2015) Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye (Lond) 29(2):258–264; quiz 265. https://doi.org/10.1038/eye.2014.315 CrossRefGoogle Scholar
- 20.Scholz P, Altay L, Fauser S (2016) Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond). https://doi.org/10.1038/eye.2016.142
- 22.Roisman L, Magalhaes FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, Farah ME (2013) Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina 44(5):465–470. https://doi.org/10.3928/23258160-20130909-08 CrossRefPubMedGoogle Scholar
- 23.Sun X, Shuai Y, Fang W, Li J, Ge W, Yuan S, Liu Q (2017) Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-311096